Therapeutics News

Complementary and alternative medicine is most often used for the treatment of chronic skin conditions rather than acute skin conditions, and herbal therapies are the most common form of treatment used, according to study results published in a research letter.

Cosmederm Bioscience announced that Woodford Investment Management is investing $50 million into the company.

A need exists for large-scale, randomized, controlled trials of systemic treatment for atopic dermatitis that include more racial and ethnic diversity to better represent the diverse U.S. population, according to a literature review.

Coronado Biosciences announced it has formed the wholly owned subsidiary, Journey Medical Corporation, to acquire and license dermatology products.

Amgen has announced that its phase 3 study evaluating the efficacy and safety of ABP 501 compared with adalimumab met its primary endpoint in the treatment of patients with moderate-to-severe plaque psoriasis.

Intralesional injection of rose bengal disodium was well-tolerated in patients with refractory cutaneous melanoma, with just over half of patients meeting the primary study endpoint, according to a poster presented at the European Society of Medical Oncology Annual Congress.

Researchers have determined rituximab to be an effective treatment for childhood and juvenile pemphigus, with no long-term complications.

The ammonia-oxidizing bacteria, Nitrosomonas, may have a future as a self-regulating topical delivery agent for nitrite and nitric oxide to the skin, according to data from a poster presented at the 5th American Society for Microbiology Conference on Beneficial Microbes.

Celgene Corporation announced that the U.S. Food and Drug Administration has approved Otezla for the treatment of patients with moderate to severe plaque psoriasis.

The Wistar Institute has announced that Meenhard Herlyn, DVM, DSc, will be the principal investigator on a $12.1 million Special Program of Research Excellence grant from the National Cancer Institute.